Skip to main content

Table 3 Association of Ki-67 and Her2 expression with pTNM stage in patients with non-metastatic gastric cancer

From: Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study

Variable

pTNM stage

χ2/F

Pa

Univariable testb

Multivariable testc

I (n = 31)

II (n = 49)

III (n = 115)

OR (95% CI)

P

OR (95% CI)

P

Ki-67

 Proportion of Ki-67-positive cells (%)

55 ± 21; 60 (50–70)

51 ± 18; 50 (40–60)

53 ± 22; 60 (40–70)

0.44

0.645

1.00 (0.99–1.01)

0.826

1.00 (0.98–1.01)

0.550

 −

4 (13)

5 (10)

12 (10)

0.53

0.469

1 (reference)

 

1 (reference)

 

 +

3 (10)

14 (29)

32 (28)

  

1.60 (0.58–4.43)

0.220

1.15 (0.35–3.79)

0.502

 ++

18 (58)

26 (53)

54 (47)

  

0.95 (0.38–2.36)

0.375

0.75 (0.26–2.19)

0.381

 +++

6 (19)

4 (8)

17 (15)

  

1.15 (0.38–3.52)

0.996

0.88 (0.25–3.14)

0.869

 Negative

7 (23)

19 (39)

44 (38)

1.85

0.174

1 (reference)

 

1 (reference)

 

 Positive

24 (77)

30 (61)

71 (62)

  

0.71 (0.40–1.27)

0.251

0.71 (0.36–1.38)

0.310

Her2

 −

17 (55)

23 (47)

62 (54)

1.41

0.236

1 (reference)

 

1 (reference)

 

 + 

3 (10)

8 (16)

27 (23)

  

1.68 (0.76–3.72)

0.338

1.89 (0.74–4.81)

0.169

 ++

7 (23)

10 (20)

16 (14)

  

0.64 (0.30–1.35)

0.220

0.57 (0.24–1.35)

0.335

 +++

4 (13)

8 (16)

10 (9)

  

0.62 (0.26–1.48)

0.250

1.68 (0.60–4.72)

0.338

 Negative

20 (65)

31 (63)

89 (77)

3.38

0.066

1 (reference)

 

1 (reference)

 

 Positive

11 (35)

18 (37)

26 (23)

  

0.55 (0.30–1.00)

0.051

0.78 (0.38–1.57)

0.482

  1. pTNM stage pathological tumor-node-metastasis stage, Her2 human epidermal growth factor receptor 2, OR odds ratio, CI confidence interval
  2. aCategorical data are shown as count (percentage [%]), and continuous data as mean ± standard deviation; median (interquartile range). The positivity degree of Her2 expression follows the National Comprehensive Cancer Network (NCCN) Guidelines (https://www.nccn.org): − means “no reactivity or membranous reactivity in < 10% of cancer cells”; + means “faint or barely perceptible membranous reactivity in ≥ 10% of cancer cells; cells are reactive only in part of their membrane”; ++ means “weak to moderate complete, basolateral or lateral membranous reactivity in ≥ 10% of cancer cells”; +++ means “strong complete, basolateral, or lateral membranous reactivity in ≥ 10% of cancer cells”. – or + expression indicates a negative result, and +++ expression suggests a positive finding. In case of ++ expression by immunohistochemistry, in situ hybridization was further performed, and cases with an average Her2 copy number ≥ 6.0 signals/cell are considered positive. For Ki-67, − means very low proliferation activity with proportion of Ki-67-positive cells < 25%; + means low proliferation activity with proportion of Ki-67-positive cells 25–50%; ++ means moderate proliferation activity with proportion of Ki-67-positive cells 50–75%; +++ means high proliferation activity with proportion of Ki-67-positive cells > 75%. A section was regarded negative in Ki-67 expression with < 50% positive cells, and positive with ≥ 50% positive cells
  3. bPerformed using univariable logistic regression
  4. cPerformed using multivariable logistic regression adjusting for sex, age, tumor location, length, and differentiation grade
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us